Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters

Journal of Clinical Oncology

Volumn 31, Issue 2, 2013, Pages 176-180

  Brauch, Hiltrud ^a,b   Schroth, Werner ^a,b   Goetz, Matthew P ^c   Mürdter, Thomas E ^a,b   Winter, Stefan ^a,b   Ingle, James N ^c   Schwab, Matthias ^a,b,d   Eichelbaum, Michel ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c MAYO CLINIC   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYTOCHROME P450 2D6; ENDOXIFEN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PRODRUG; SOMATOMEDIN C; TAMOXIFEN; TOLMETIN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DECISION MAKING; DRUG DOSE INCREASE; ENZYME METABOLISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; HUMAN; MENOPAUSE; MONOTHERAPY; NOTE; PHARMACOGENETICS; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDENOLIDES; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; SAPONINS; TAMOXIFEN;

EID: 84872587241     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.6625     Document Type: Note

References (36)

1. Regan MM, Leyland-Jones B, Bouzyk M, et al: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J Natl Cancer Inst 104:441-451, 2012
2. Rae JM, Drury S, Hayes DF, et al: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452-460, 2012
3. Kelly CM, Pritchard KI: CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: Lessons learned. J Natl Cancer Inst 104:427-428, 2012
4. Nakamura Y, Ratain MJ, Cox NJ, et al: Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J Natl Cancer Inst 104:1264, 2012
5. Stanton V Jr: Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J Natl Cancer Inst 104:1265-1266, 2012
6. Pharoah PD, Abraham J, Caldas C: Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:1263-1264, 2012
7. Rae JM: Personalized tamoxifen: What is the best way forward? J Clin Oncol 29:3206-3208, 2011
8. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
9. Schroth W, Goetz MP, Hamann U, et al: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436, 2009
10. Abraham JE, Maranian MJ, Driver KE, et al: CYP2D6 gene variants: Association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12:R64, 2010
11. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005
12. The Human Cytochrome P450 (CYP) Allele Nomenclature Committee: The human cytochrome P450 (CYP) allele nomenclature database. http://www.cypalleles.ki.se/
13. PharmGKB: Well-known pharmacogenomics associations. http://www.pharmgkb. org/search/knownPairs.action
14. Castells A, Gusella JF, Ramesh V, et al: A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 60:2836-2839, 2000 (Pubitemid 30395802)
15. Hirano A, Utada Y, Haga S, et al: Allelic losses as prognostic markers for breast cancers. Int J Clin Oncol 6:6-12, 2001 (Pubitemid 32230356)
16. Loo LW, Ton C, Wang YW, et al: Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer 47:1049-1066, 2008
17. Rae JM, Hayes DF, Cuzick J, et al: Response. J Natl Cancer Inst [epub ahead of print on July 31, 2012]
18. Regan MM, Bouzyk M, Rae JM, et al: Response. J Natl Cancer Inst [epub ahead of print on July 31, 2012]
19. Schroth W, Hamann U, Fasching PA, et al: CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification. Clin Cancer Res 16:4468-4477, 2010
20. Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9:576-586, 2009
21. Brauch H, Mürdter TE, Eichelbaum M, et al: Pharmacogenomics of tamoxifen therapy. Clin Chem 55:1770-1782, 2009
22. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003 (Pubitemid 38008898)
23. Brauch H, Jordan VC: Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach? Eur J Cancer 45:2274-2283, 2009
24. Dowsett M, Haynes BP: Hormonal effects of aromatase inhibitors: Focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 86:255-263, 2003 (Pubitemid 37412564)
25. Lash TL, Lien EA, Sørensen HT, et al: Genotype-guided tamoxifen therapy: Time to pause for reflection? Lancet Oncol 10:825-833, 2009
26. Wu X, Hawse JR, Subramaniam M, et al: The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722-1727, 2009
27. Johnson MD, Zuo H, Lee KH, et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159, 2004 (Pubitemid 38987269)
28. Ratliff B, Dietze EC, Bean GR, et al: Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 96:883, 2004
29. Kochansky CJ, McMasters DR, Lu P, et al: Impact of pH on plasma protein binding in equilibrium dialysis. Mol Pharm 5:438-448, 2008 (Pubitemid 351929828)
30. Decensi A, Robertson C, Viale G, et al: A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779-790, 2003 (Pubitemid 36798424)
31. Irvin WJ Jr, Walko CM, Weck KE, et al: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol 29:3232-3239, 2011
32. Mürdter TE, Schroth W, Bacchus-Gerybadze L, et al: Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717, 2011
33. Barginear MF, Jaremko M, Peter I, et al: Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: Effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 90:605-611, 2011
34. Borges S, Desta Z, Li L, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006 (Pubitemid 43946844)
35. Mauvais-Javis P, Baudot N, Castaigne D, et al: Trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 46:1521-1525, 1986 (Pubitemid 16048306)
36. McLeod HL, Isaacs KL: Preemptive pharmacogenetic testing: Insufficient data equal unsatisfactory guidance. Ann Intern Med 154:842-844, 2011